EXCLUSIVE: Trump’s FDA nominee vows new abortion pill safety review after pressure from Sen Hawley
A prospective FDA commissioner nominee pledges a structured safety review of the abortion pill mifepristone amid pressure from Sen. Hawley, signaling a path to reimpose safeguards erased under the Biden administration. Hawley asserts the commitment would formalize data-driven timelines, aiming for a final study by March 2027 and regulatory actions by September 2027, with findings applying to both brand-name and generic versions. The confirmation fight centers on heightened scrutiny of abortion-drug oversight since 2023, and pro-life groups argue this could restore key protections. The discourse foreshadows potential policy shifts as the administration negotiates the balance between scientific review and access to medication. The outcome hinges on Senate action and the FDA’s adherence to the review schedule and resulting reforms.
Dive Deeper:
Sen. Josh Hawley secured commitments from FDA nominee Dr. Heidi Overton to establish a binding timeline and data parameters for a safety study on mifepristone, with a plan to finalize the study by March 2027 and implement FDA changes by September 2027. Updated safety protocols would cover both brand-name and generic versions of mifepristone.
The study will utilize Medicaid and commercially available data from periods before and after the Biden administration lifted certain dispensing and in-person-visit requirements, reflecting a broad data scope across regulatory changes.
Hawley has framed the push as part of a broader pro-life effort, arguing that the drug’s dangers necessitate accountability and that Congress must act on safety concerns, including potential liability issues for manufacturers.
Opposition commentary from pro-life groups centered on the absence of commitments to restore in-person dispensing requirements and to address concerns about the agency’s safety data review, which they say influenced opposition to Overton’s confirmation.
The FDA review has faced repeated postponements despite prior pledges to release a study in 2025, leading to criticism that critical data may have been excluded from the assessment.
Overton indicated willingness to complete the review expeditiously while preserving scientific integrity, and she emphasized transparency about the evidence and results to the extent permitted by law.
The political dynamic includes discussions of potential legislative proposals to ban mifepristone, and Hawley’s statements highlighted the perceived dangers of the drug and the importance of tighter regulatory oversight.